The takeaway
Vor Biopharma Inc shows a pronounced seasonal pattern over 5 years of data — strongest in December (+31.6%) and softest in May (−28.0%).
Right now
In July, the stock has fallen 40% of years, averaging −0.2%, roughly 2.4 pts behind the S&P 500.
The full picture
Vor Biopharma Inc's most dependable month has been December, higher in 5 of 5 years; May has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | — | |||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | — |
Month by month
The stock's clearest edge over the S&P 500 lands in December (+30.6 pts); it has trailed the market most in May (−28.7 pts).
“vs S&P” is Vor Biopharma Inc’s average for a month minus the S&P 500’s average for that same month — isolating Vor Biopharma Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, December has closed higher 100% of the time versus 100% across the last 5 years — the pattern is holding.
Figures are the typical (median) December return and how often it rose — the last 5 years versus the last 5(the heatmap’s default window). This verdict stays anchored to that 5-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: December, up in all 5 Decembers while the other eleven tend to blur together.
Its average (+31.6%) and median (+27.7%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even December ranges by 22.9% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: December has cleared the S&P 500 by +30.6 points above the index. That consistency sets it apart from the field, where the average stock manages December only about 58% of the time.
A few other months pull their weight: February and October have also closed higher more often than not. On the other side of the ledger, May has been the soft spot — the weakest of 8 months that average a loss (−28.0%), and the edge isn't year-round — the stock has trailed the S&P 500 in May, November, and April. Its roughest month on record was a −69.7% May in 2025 — a reminder of how hard even a seasonal name can fall.
December has now closed higher 5 years running.
The takeaway is less about when to buy than what to expect: December aside, the stock's months offer little reliable tilt. With a short 5-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (December), its worst (May), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2021 its best month (December, +31.6%) has run well ahead of its worst (May, −28.0%) — the heatmap above shows how steady that gap has been year to year.
December has been the strongest, averaging +31.6% and closing higher in all 5 years on record since 2021.
It's the weakest, averaging −28.0% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade